

ASX Release

8<sup>th</sup> April 2015

## **LYELL McEWIN HOSPITAL IN ADELAIDE IS APPROVED TO JOIN PHARMAUST'S CANCER TRIAL**

*APPROVAL HAS BEEN RECEIVED FROM THE ROYAL ADELAIDE HOSPITAL RESEARCH ETHICS COMMITTEE AND FROM THE GOVERNANCE OFFICE TO START EVALUATING PPL-1 AT A SECOND SITE (LYELL MCEWIN HOSPITAL)*

**PharmAust Limited** ("PharmAust") (ASX: PAA & PAAO) is pleased to report that it has received approval from both the Royal Adelaide Hospital (RAH) Ethics Committee and the Royal Adelaide Hospital Governance Committee to begin evaluation of proprietary drug PPL-1 at the Lyell McEwin Hospital (LMH), Elizabeth Vale, Adelaide, South Australia. Following the Trial Safety Committee approval of dose-escalation of PPL-1 in accordance with the protocol, recruitment will now take place both at the RAH and Lyell McEwin Hospital enabling faster progress in the treatment of patients at the next treatment doses.

Dr Rohit Joshi, Consultant Medical Oncology and Director for Cancer Research and Clinical Trials, will recruit and treat patients at the Lyell McEwin Hospital for PharmAust. Dr Joshi said "We will be treating patients who have failed "Standard of Care" and have no further options under the currently available treatment regimens. PPL-1 is a potential new class of anticancer drug and we note the progress achieved to date at the RAH".

PharmAust's Executive Chairman Dr Roger Aston said "This additional cancer centre based at the Lyell McEwin Hospital should enhance our patient recruitment capabilities. We still have two dosage levels to complete in our Phase I/II rising dose trial (25mg/kg and 62.5mg/kg) each of which requires the recruitment of three patients. PharmAust will report on safety and tumour marker levels during the treatment of each patient treated".

The cancer chemotherapy market (estimated at \$42 billion/annum)\* is currently the fastest growing sector within the pharma industry, mainly driven by the identification of new potential therapeutic targets. This growth is further fuelled by the magnitude of the disease worldwide, currently estimated at more than 25 million people suffering from cancer globally, and an estimated 5 million people dying each year from the disease.

\*Reference: Research and Markets.com accessed 14<sup>th</sup> February 2014:  
[http://www.researchandmarkets.com/reports/335548/chemotherapy\\_market\\_insights\\_20062016\\_a](http://www.researchandmarkets.com/reports/335548/chemotherapy_market_insights_20062016_a)

**For further details please contact:**

**Dr Roger Aston**  
Executive Chairman  
Tel: 0402 762 204  
[rogeraston@pharmaust.com](mailto:rogeraston@pharmaust.com)

**Mr Robert Bishop**  
Executive Director  
Tel: 0417 445 180  
[robertbishop@pharmaust.com](mailto:robertbishop@pharmaust.com)